Tumor Biology

, 32:1113 | Cite as

The expression of p33ING1, p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer

  • Jun Liu
  • Yongping Lin
  • Haihong Yang
  • Qiuhua Deng
  • Guoqin Chen
  • Jianxing He
Research Article

Abstract

The purpose of this study was to investigate the expressions of tumor inhibitor of growth (ING1) gene p33ING1, p53, and autophagy-related gene Beclin1 in human non-small cell lung cancer (NSCLC), and the correlation between their expressions with clinical pathological features and clinical significance. The research can provide new ideas and experimental evidence for early diagnosis and biotherapy for NSCLC in the future. The human NSCLC tissues and surrounding non-cancerous tissues were collected from surgical operation. The expressions of mRNA or protein of p33ING1, p53, and Beclin1 were detected by using of reverse transcription polymerase chain reaction or Western blot in these tissues. The results were used to analyze the relationships between these gene expressions with the developing of NSCLC and clinical pathological features. The expressions of mRNA or protein of p33ING1 and Beclin1 in NSCLC tissues were significantly lower than that in surrounding noncancerous tissues (p < 0.05). The expressions of mRNA or protein of p33ING1 and Beclin1 in well- and middle-differentiated NSCLC tissues were lower than those in poor-differentiated NSCLC tissues (p < 0.05). The expressions of mRNA or protein of p33ING1 and Beclin1 in presence of lymph nodes metastasis were lower than those in absence of lymph nodes metastasis (p < 0.05). The expressions of mRNA or protein of p33ING1 and Beclin1 in patients of pathological stage (stages I–II) were higher than those in pathological stage (stages III–IV) (p < 0.05). But the expression of protein of mutant-type p53 in NSCLC tissues was significantly higher than that in surrounding non-cancerous tissues (p < 0.05). The expressions of protein of mutant-type p53 in well- and middle-differentiated NSCLC tissues were higher than those in poor-differentiated NSCLC tissues (p < 0.05). The expressions of protein of mutant-type p53 in presence of lymph nodes metastasis were higher than those in absence of lymph nodes metastasis (p < 0.05). The expressions of protein of mutant-type p53 in patients of pathological stage (stages I–II) were lower than those in pathological stage (stages III–IV) (p < 0.05). These expression changes of p33ING1, p53, and autophagy-related Beclin1 genes were associated with tumor cell differentiation, lymph nodes metastasis, and pathological stage of NSCLC. But these expression changes of these three genes were not associated with gender, age, size of primary carcinoma, histological type of NSCLC (p > 0.05). The expression of mRNA of p53 and Beclin1 were correlated with p33ING1 mRNA expression in NSCLC tissues (p < 0.05). The activity changes of tumor inhibitor of growth, autophagy, and apoptosis may be related to the emergence and the development of NSCLC. The combined detection of p33ING1, p53, and Beclin1 genes and proteins will be helpful for early diagnosis and prognosis judgment for NSCLC, and can provide experimental evidence for biotherapy of NSCLC.

Keywords

p33ING1 p53 Beclin1 Non-small cell lung cancer (NSCLC) RT-PCR Western blot 

Notes

Conflicts of interest

None.

References

  1. 1.
    Smith CB, kelley AS, Meier DE. Evidence for new standard of care in non-small cell lung cancer patients. Semin Thorac Cardiovasc Surg. 2010;22:193–4.PubMedCrossRefGoogle Scholar
  2. 2.
    McKeage MJ, Jameson MB, AS1404-201 Study Group Investigators. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) – retrospective analysis of pooled data. J Thorac Dis. 2010;2:199–204.Google Scholar
  3. 3.
    Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: are we making progress? J Thorac Dis. 2011;3:19–29.Google Scholar
  4. 4.
    Shao WL, Wang DY, He JX. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis. 2010;2:89–99.Google Scholar
  5. 5.
    Shash E, Peccatori FA, Azim Jr HA. Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). J Thorac Dis. 2011;3:57–64.Google Scholar
  6. 6.
    Xiao DK, He JX. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2:154–9.Google Scholar
  7. 7.
    Yang HH, Zhang Q, He JX, Lu WJ. Regulation of calcium signaling in lung cancer. J Thorac Dis. 2010;2:52–6.Google Scholar
  8. 8.
    Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des. 2011;17:631–9.PubMedGoogle Scholar
  9. 9.
    Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192:209–18.PubMedCrossRefGoogle Scholar
  10. 10.
    Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4:3017–24.PubMedGoogle Scholar
  11. 11.
    Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol. 2011;2011:603925.PubMedCrossRefGoogle Scholar
  12. 12.
    Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet. 1996;14:415–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Garkavtsev I, Demetrick D, Riabowol K. Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). Cytogenet Cell Genet. 1997;76:176–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Zeremski M, Horrigan SK, Grigorian IA, Westbrook CA, Gudkov AV. Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34. Somat Cell Mol Genet. 1997;23:233–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Jager D, Stockert E, Scanlan MJ, Gure AO, Jager E, Knuth A, et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res. 1999;59:6197–204.PubMedGoogle Scholar
  16. 16.
    Saito A, Furukawa T, Fukushige S, Koyama S, Hoshi M, Hayashi Y, et al. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p33/ING1. J Hum Genet. 2000;45:177–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Gunduz M, Demircan K, Gunduz E, Katase N, Tamamura R, Nagatsuka H. Potential usage of ING family members in cancer diagnostics and molecular therapy. Curr Drug Targets. 2009;10:465–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Menendez C, Abad M, Gomez-Cabello D, Moreno A, Palmero I. ING proteins in cellular senescence. Curr Drug Targets. 2009;10:406–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Shah S, Smith H, Feng X, Rancourt DE, Riabowol K. ING function in apoptosis in diverse model systems. Biochem Cell Biol. 2009;87:117–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Gunduz M, Gunduz E, Rivera RS, Nagatsuka H. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets. 2008;8:275–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Cheung Jr KJ, Li G. The tumor suppressor ING1: structure and function. Exp Cell Res. 2001;268:1–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics. 1999;59:59–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2001;2:330–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Meschini S, Condello M, Lista P, Arancia G. Autophagy: molecular mechanisms and their implications for anticancer therapies. Curr Cancer Drug Targets. 2011;11:357–79.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen N, Karantza V. Autophagy as a therapeutic target in cancer. Cancer Biol Ther. 2011;11:157–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Cheung Jr KJ, Mitchell D, Lin P, Li G. The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA. Cancer Res. 2001;61:4974–7.PubMedGoogle Scholar
  28. 28.
    Gong W, Suzuki K, Russell M, Riabowol K. Function of the ING family of PHD proteins in cancer. Int J Biochem Cell Biol. 2005;37:1054–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Nouman GS, Anderson JJ, Lunec J, Angus B. The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol. 2003;56:491–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Kameyama K, Huang CL, Liu D, Masuya D, Nakashima T, Sumitomo S, et al. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. Clin Cancer Res. 2003;9:4926–34.PubMedGoogle Scholar
  31. 31.
    Guo XB, Jing CQ, Li LP, Zhang L, Shi YL, Wang JS, et al. Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. World J Gastroenterol. 2011;17:1895–902.PubMedGoogle Scholar
  32. 32.
    Charoenkwan P, Senger C, Weitzman S, Sexsmith E, Sherman CG, Malkin D, et al. Significance of p53 expression in immature teratomas. Pediatr Dev Pathol. 2002;5:499–507.PubMedCrossRefGoogle Scholar
  33. 33.
    Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87–98.PubMedCrossRefGoogle Scholar
  34. 34.
    Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011;18:271–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Grander D, Panaretakis T. Autophagy: cancer therapy's friend or foe? Future Med Chem. 2010;2:285–97.PubMedCrossRefGoogle Scholar
  36. 36.
    Edinger AL, Thompson CB. Defective autophagy leads to cancer. Cancer Cell. 2003;4:422–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Chen N, Karantza-Wadsworth V. Role and regulation of autophagy in cancer. Biochim Biophys Acta. 2009;1793:1516–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Won KY, Kim GY, Kim YW, Song JY, Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol. 2010;41:107–12.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • Jun Liu
    • 1
    • 2
  • Yongping Lin
    • 3
  • Haihong Yang
    • 1
    • 2
  • Qiuhua Deng
    • 1
    • 2
  • Guoqin Chen
    • 4
  • Jianxing He
    • 1
    • 2
  1. 1.Department of Cardiothoracic SurgeryThe First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouPeople’s Republic of China
  2. 2.Guangzhou Institute of Respiratory Diseases & China State Key Laboratory of Respiratory DiseaseGuangzhouChina
  3. 3.Department of Molecular ImmunologyThe First Affiliated Hospital of Guangzhou Medical CollegeGuangzhouChina
  4. 4.Department of PathologyThe First Affiliated Hospital of Guangzhou Medical CollegeGuangzhouChina

Personalised recommendations